LanzaTech Global, Inc.

LNZA
Country: United StatesPrice: $3.85Market Cap: $50.4M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

All 10 investors flag LNZA's cash flow

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #3026 (Top 97.7%)PASSFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Cash Flow0% pass✗ 12▾

      All 10 investors flag LNZA's cash flow

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing$-33.8M
      ✗LynchPositive and growing
      Operating Cash Flow$-64.9M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-64.72%, ROA=-48.85%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-131.2%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/4 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-378.4%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/5 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-33.8M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-67.08%; #3944/4519 (top 87.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -68.3% vs Rev: 12.6%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth12.6%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -169.9% -> -141.7%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Profitability6% pass✓ 9✗ 26▾

      15 of 16 flag LNZA's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/6 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/6 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-570.7%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-141.7% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE66.1%
      ✓Lynch> 15%
      EBIT / Enterprise Value-212.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-212.6%, ROC=-496.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-48.85%
      ✗PiotroskiROA > 0
      ROA Change YoY-78.85% -> -48.85% (delta: +30.00%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-64.72%, ROA=-48.85%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-80.1%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity66.1%
      ✓Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-570.7% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-61.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity66.1%
      ✓Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-169.9% (2023) -> -141.7% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -169.9% -> -141.7%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization+342.12%; #42/6340 (top 0.7%)
      ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity+66.15%; #150/5226 (top 2.9%)
      ✓AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.2570; #4472/5884 (top 76.0%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 14▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #3026✓PiotroskiPASS (F-Score 4)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag LNZA's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities2.48
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Valuation8% pass✓ 4✗ 24▾

      12 of 13 flag LNZA's valuation — Graham, Lynch, Greenblatt +9 more

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-212.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-212.6%, ROC=-496.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-131.2%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($3.85)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization+342.12%; #42/6340 (top 0.7%)
      ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+5.1720; #282/6449 (top 4.4%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+1.1571; #1615/5247 (top 30.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-67.08%; #3944/4519 (top 87.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-37.50%; #4711/6202 (top 76.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag LNZA's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio2.48
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-131.2%
      ✗Buffett> 10%
      ROIC - WACC-141.2%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-496.9%
      ✗Greenblatt> 25%
      Current Ratio Change YoY3.26 -> 1.43
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.28x -> 0.56x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities2.48
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-60.2%; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/1 years above 12% (latest -60.2%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Chemicals
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($50.4M)
    Revenue: $55.8M+12.6% YoY
    Net Income: $49.0M+64.5% YoY

    Financial Snapshot

    Operating Margin-141.7%
    Return on Equity1257.7%
    Debt / Equity--
    Current Ratio1.43
    EPS (Diluted)$-22.27
    Buybacks (1y)$0
    Buybacks (2y)$48.0K

    Shareholder Return

    Fiscal 2025

    Share retirement not available for this company.

    Buybacks
    $0
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex, buybacks, revenue, net income, operating income, ebit.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-04-15
    FY 2023
    Sources
    • 10-K · 2024-02-29
    FY 2022
    Sources
    • 10-K · 2023-03-29
    FY 2021
    Sources
    • 10-K · 2023-03-29
    Market Cap$50.4Mcurrent----$27.8Mest.$183.6Mest.$85.6Best.$10.7Best.--
    Revenue$58.3M↑44%$9.0M↓1%$12.0M↑27%$55.8M↑13%$49.6M↓21%$62.6M↑68%$37.3M--
    Operating Income-$35.5M↑71%-$9.9M↑69%-$9.8M↑68%-$79.2M↑27%-$108.9M↓2%-$106.4M↓41%-$75.6M↓5347%-$1.4M
    Net Income$172.4M↑227%$184.3M↑667%-$14.7M↑24%-$49.0M↑64%-$137.7M↓3%-$134.1M↓76%-$76.4M↓163470%$46.7K
    EPS (Diluted)--$15.81↑10640%$-1.77↓1670%$-22.27↓3081%$-0.70↑11%$-0.79↑94%$-12.37--
    Gross Margin————————
    Operating Margin-61.0%↑80%-109.5%↑69%-81.6%↑75%-141.7%↑35%-219.7%↓29%-169.9%↑16%-202.4%—
    ROE66.1%↓88%——1257.7%↑223%-1024.3%↓774%-117.1%↓758%17.8%↑135346%-0.0%
    Total Debt----------$25.1M↓50%$50.0M--
    Shareholders' Equity$260.6M↑1135%$260.6M↑1135%$48.1M↑4194%-$3.9M↓129%$13.4M↓88%$114.5M↑127%-$428.7M↓21%-$354.9M
    Current Ratio2.48↑109%2.48↑109%1.96↓10%1.43↓56%3.26↓48%6.22↑181%2.21↑144%0.91
    Debt / Equity—————0.22↑288%-0.12—
    Operating Cash Flow-$32.7M↑63%-$1.4M↑94%-$9.3M↑56%-$64.9M↑27%-$89.1M↑8%-$97.3M↓15%-$84.7M↓16508%-$510.0K
    Free Cash Flow-$33.8M↑63%-$2.1M↑91%-$9.3M↑57%-$66.1M↑30%-$94.4M↑11%-$105.8M↓11%-$95.4M--

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Chemicals

    LNZA vs Peers — Financial Grading

    Revenue$55.8MBottom 25%
    Net Income$49.0MBottom 25%
    ROE1257.7%Top 25%
    D/E—
    Op. Margin-141.7%Bottom 25%
    Curr. Ratio1.43Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    EIDP, Inc.CTA-PB$46.8B$54.21——————2/95/92/70/3F-Score 14/11
    CF Industries Holdings, Inc.CF$18.3B$125.09$7.1B$1.8B37.2%0.6632.5%3.373/94/95/73/3F-Score 88/11
    RPM INTERNATIONAL INC/DE/RPM$13.2B$103.73$7.9B$661.4M20.0%0.77—1.683/92/93/71/3F-Score 67/11
    Element Solutions IncESI$8.0B$33.08$2.6B$190.8M7.1%0.6113.4%3.682/92/91/71/3F-Score 56/11
    NEWMARKET CORPNEU$6.5B$709.19$2.7B$418.7M23.5%0.5020.0%2.534/96/92/71/3F-Score 55/11
    HEXCEL CORP /DE/HXL$6.0B$79.46$1.9B$109.4M8.7%0.799.1%2.262/92/93/70/3F-Score 64/11
    ICL Group Ltd.ICL$5.8B$4.52$7.2B$226.0M3.8%0.468.1%1.335/94/92/70/3F-Score 45/11
    BALCHEM CORPBCPC$5.5B$173.14$1.0B$154.8M12.3%0.1320.2%2.072/94/92/71/3F-Score 95/11